| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | INPP5K |
| Uniprot No | Q9BT40 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-448aa |
| 活性数据 | MSSRKLSGPKGRRLSIHVVTWNVASAAPPLDLSDLLQLNNRNLNPDIYVIGLQELNSGIISLLSDAAFNDSWSSFLMDVLSPLSFIKVSHVRMQGILLLVFAKYQHLPYIQILSTKSTPTGLFGYWGNKGGVNICLKLYGYYVSIINCHLPPHISNNYQRLEHFDRILEMQNCEGRDIPNILDHDLIIWFGDMNFRIEDFGLRFVRESIKNRCYGGLWEKDQLSIAKKHDPLLREFQEGRLLFPPTYKFDRNSNDYDTSEKKRKPAWTDRILWRLKRQPCAGPDTPIPPASHFSLSLRGYSSHMTYGISDHKPVSGTFDLELKPLVSAPLIVLMPEDLWTVENDMMVSYSSTSDFPSSPWDWIGLYKVGLRDVNDYVSYAWVGDSKVSCSDNLNQVYIDISNIPTTEDEFLLCYYSNSLRSVVGISRPFQIPPGSLREDPLGEAQPQI |
| 分子量 | 74.8 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4篇关于重组人INPP5K蛋白的参考文献示例及摘要内容概要：
---
1. **文献名称**：*"Recombinant human INPP5K phosphatase: purification, enzymatic activity, and structural insights"*
**作者**：Osborne, S.L. et al.
**摘要**：该研究通过大肠杆菌系统成功表达并纯化了重组人INPP5K蛋白，验证其特异性水解磷脂酰肌醇底物的酶活性，并通过X射线晶体学解析了其三维结构，揭示了催化活性位点的关键氨基酸残基。
---
2. **文献名称**：*"INPP5K regulates insulin signaling through phosphatidylinositol modulation in diabetic models"*
**作者**：Volmers, R. & Thomas, C.C.
**摘要**：研究人员利用重组人INPP5K蛋白在小鼠模型中发现，该蛋白通过调控PI(4.5)P2和PI(3.4.5)P3的动态平衡影响胰岛素信号通路，其表达异常与胰岛素抵抗相关，提示其在2型糖尿病中的潜在治疗靶点。
---
3. **文献名称**：*"Loss-of-function mutations in INPP5K cause congenital muscular dystrophy via dysregulated ER homeostasis"*
**作者**：Wiessner, M. et al.
**摘要**：该研究结合患者基因测序和体外重组INPP5K功能实验，证明INPP5K突变导致内质网应激和肌肉细胞凋亡，重组蛋白的补充可部分恢复细胞稳态，为先天性肌病的机制研究和基因治疗奠定基础。
---
4. **文献名称**：*"High-throughput screening identifies small molecule inhibitors of INPP5K for cancer therapy"*
**作者**：Zhang, Y. et al.
**摘要**：通过基于重组INPP5K蛋白的高通量筛选，发现多个抑制其磷酸酶活性的化合物，并在肿瘤细胞中验证其抑制PI3K/AKT通路的能力，提示INPP5K可能作为癌症治疗的分子靶标。
---
**备注**：以上文献信息为示例性概括，实际研究中需根据具体实验背景检索并引用相关文献。如需真实文献，建议通过PubMed或SciHub以关键词“INPP5K recombinant”或“INPP5K phosphatase”查询近年研究。
Recombinant human INPP5K (inositol polyphosphate-5-phosphatase K), also known as SKIP or SPRP, is a ubiquitously expressed enzyme belonging to the phosphoinositide 5-phosphatase family. It catalyzes the hydrolysis of phosphatidylinositol-4.5-bisphosphate [PI(4.5)P₂] and phosphatidylinositol-3.4.5-trisphosphate [PI(3.4.5)P₃], regulating key signaling pathways involved in cell growth, membrane trafficking, and cytoskeletal organization. INPP5K localizes to the endoplasmic reticulum (ER) through its C-terminal domain and plays a role in ER stress response and unfolded protein response. Its enzymatic activity is linked to maintaining ER morphology and cellular homeostasis. Mutations in the INPP5K gene are associated with congenital muscular dystrophy, intellectual disability, and cataracts, highlighting its importance in neuromuscular and neurological functions. Recombinant INPP5K protein is widely used in biochemical studies to investigate phosphoinositide metabolism, ER-mitochondria communication, and disease mechanisms. Produced via heterologous expression systems (e.g., E. coli or mammalian cells), it retains catalytic activity and structural features critical for substrate interaction. Research applications include enzyme kinetics, protein-protein interaction assays, and functional studies in cellular models of genetic disorders. The protein’s role in modulating insulin signaling and autophagy further expands its relevance in metabolic and age-related disease research.
×
